Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Kodiak Sciences Inc.

KOD · Nasdaq · CIK 0001468748 · Healthcare · Biotechnology

INSIDER SIGNAL

69.0 / 100

1 buyers · 82 purchase transaction lines · $157.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeStrong
RoleStrong
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+24.8 / 25
Role+20.0 / 20
Recency+7.3 / 10
Conviction+9.9 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ✓ Role scores high · most senior buyer: Director,TenPercentOwner
  • ✓ Recent activity · latest purchase 2026-09-29

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPDirector,TenPercentOwner
●●●●
BORGESON JOHN A.Chief Financial Officer
○▼
PERLROTH VICTORChairman and CEO
○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: 667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP · $157.0M
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-09-28–2026-09-29

Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

69.0 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 69.6
  2. 69.4
  3. 69.3
  4. 69.2
  5. 69.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

84Purchases
6Sales
8Other Form 4 lines
10SEC filings · 365 days
BUYING82 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER4 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDUnavailable

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+203.8%
3M
+143.0%
6M
+131.7%
12M
+590.7%

Volatility & liquidity

Volatility
172.0%
Beta
—
Avg daily value
USD 160.0M

Valuation

Market cap
USD 6.3B
P/E
—

Fundamentals

Profit margin
—
ROE
-146.1%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
9,376,012
Previous report
10,672,646
Avg daily volume
5,205,761
Days to cover
1.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-29667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock33,726USD 85.04USD 2,868,175SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock681,866USD 88.77USD 60,530,796SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock418,323USD 83.58USD 34,962,746SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock807,840USD 72.57USD 58,627,586SEC filing ↗
2025-12-18667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock2,608,696USD 23.00USD 60,000,008SEC filing ↗
2022-06-06667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock303,917USD 7.77USD 2,361,076SEC filing ↗
2022-06-03667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock102,200USD 7.95USD 812,196SEC filing ↗
2022-06-02667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock166,232USD 7.67USD 1,274,650SEC filing ↗
2022-05-27667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock155,940USD 6.87USD 1,070,998SEC filing ↗
2022-05-26667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock93,322USD 6.74USD 628,634SEC filing ↗
2022-05-25667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock101,144USD 6.56USD 663,777SEC filing ↗
2022-05-18667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock223,766USD 5.97USD 1,335,678SEC filing ↗
2022-05-17667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock110,824USD 5.99USD 663,836SEC filing ↗
2022-05-16667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock122,100USD 5.72USD 697,871SEC filing ↗
2022-02-17667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock300,000USD 54.56USD 16,366,800SEC filing ↗

Form 4 evidence

98 transaction lines in the latest 365-day window; 518 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-29667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock33,726USD 85.04USD 2,868,175SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock681,866USD 88.77USD 60,530,796SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock418,323USD 83.58USD 34,962,746SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-29667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock33,726USD 85.04USD 2,868,175SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock681,866USD 88.77USD 60,530,796SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock418,323USD 83.58USD 34,962,746SEC filing ↗
2026-09-28667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock807,840USD 72.57USD 58,627,586SEC filing ↗
2026-09-25PERLROTH VICTOROption exercise / conversion (M)Common Stock1,280,524USD 4.20USD 5,381,943SEC filing ↗
2026-06-04BORGESON JOHN A.Sale (S)Common Stock30,000USD 34.10USD 1,023,009SEC filing ↗
2026-06-04BORGESON JOHN A.Option exercise / conversion (M)Common Stock30,000USD 1.04USD 31,200SEC filing ↗
2026-04-15BORGESON JOHN A.Option exercise / conversion (M)Common Stock28,614USD 1.04USD 29,759SEC filing ↗
2026-04-02BORGESON JOHN A.Sale (S)Common Stock30,000USD 39.92USD 1,197,488SEC filing ↗
2026-04-02BORGESON JOHN A.Option exercise / conversion (M)Common Stock30,000USD 1.04USD 31,200SEC filing ↗
2026-03-25PERLROTH VICTOROption exercise / conversion (M)Common Stock300,000USD 1.04USD 312,000SEC filing ↗
2025-12-26PERLROTH VICTORGift (G)Common Stock12,500USD 0.00USD 0SEC filing ↗
2025-12-18667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LPPurchase (P)Common Stock2,608,696USD 23.00USD 60,000,008SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerKOD
CIK0001468748
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history518 transaction lines from 2020-02-24 to 2026-09-29
305 P purchase lines · 152 S sale lines · 61 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.